CD274 and non-small cell lung carcinoma: Recently, immune checkpoint inhibitors (ICIs), represented by programmed cell death-1 (PD-1) and programmed cell death-ligand 1(PD-L1) monoclonal antibodies, have presented a new approach for NSCLC treatment (5, 6).